Raymond James Financial Services Advisors, Inc. - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.

Quarter-by-quarter ownership
Raymond James Financial Services Advisors, Inc. ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$1,515,027
-1.6%
33,378
+21.7%
0.00%0.0%
Q2 2023$1,539,920
+15.9%
27,430
-6.6%
0.00%0.0%
Q1 2023$1,328,269
+19.8%
29,367
+7.7%
0.00%
+50.0%
Q4 2022$1,108,322
-35.5%
27,265
+3.7%
0.00%
-50.0%
Q3 2022$1,717,000
+35.9%
26,280
+26.5%
0.00%
+33.3%
Q2 2022$1,263,000
-17.3%
20,782
-14.7%
0.00%0.0%
Q1 2022$1,528,000
-46.2%
24,350
-35.0%
0.00%
-40.0%
Q4 2021$2,841,000
-13.9%
37,490
+27.2%
0.01%
-28.6%
Q3 2021$3,299,000
+2.4%
29,472
+48.0%
0.01%0.0%
Q2 2021$3,223,000
-4.6%
19,908
-28.2%
0.01%
-12.5%
Q1 2021$3,380,000
+1.7%
27,742
+27.9%
0.01%0.0%
Q4 2020$3,322,000
+160.1%
21,698
+42.1%
0.01%
+100.0%
Q3 2020$1,277,000
+36.7%
15,267
+20.1%
0.00%
+33.3%
Q2 2020$934,000
+103.5%
12,707
+17.4%
0.00%
+50.0%
Q1 2020$459,000
-30.1%
10,824
+0.3%
0.00%0.0%
Q4 2019$657,000
+75.7%
10,787
+18.4%
0.00%
+100.0%
Q3 2019$374,000
-6.5%
9,114
+7.2%
0.00%
-50.0%
Q2 2019$400,000
+51.5%
8,503
+14.9%
0.00%
+100.0%
Q1 2019$264,000
+22.8%
7,401
-1.5%
0.00%0.0%
Q4 2018$215,000
-62.7%
7,511
-42.3%
0.00%
-66.7%
Q3 2018$577,000
-24.6%
13,0140.0%0.00%
-25.0%
Q2 2018$765,00013,0140.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders